[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cassella James V reported acquisition or exercise transactions in this Form 4 filing.

Trevi Therapeutics, Inc. reported that Chief Development Officer James V. Cassella received a grant of stock options covering 215,000 shares of common stock on February 19, 2026. The options were granted at a price of $0.0000 per share as a compensation award.

The 215,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and vesting depends on Cassella’s continued service with the company. Following this award, he holds stock options for 215,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cassella James V

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	215,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 215,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cassella James V

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.56	02/19/2026		A		215,000		(1)	02/18/2036	Common Stock	215,000	$0	215,000	D

Explanation of Responses:

1. This option was granted on February 19, 2026. The 215,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

	/s/ Christopher Galletta, attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Trevi Therapeutics (TRVI) report for James V. Cassella?

Trevi Therapeutics reported a stock option grant to Chief Development Officer James V. Cassella. He was awarded options for 215,000 shares of common stock on February 19, 2026, as a compensation-related acquisition rather than an open-market stock purchase or sale.

How many Trevi Therapeutics (TRVI) shares are covered by the new stock option grant?

The new stock option grant covers 215,000 shares of Trevi Therapeutics common stock. These shares are underlying a single stock option award and will vest in equal monthly installments through February 19, 2030, assuming the executive continues serving with the company throughout that period.

What is the vesting schedule for James V. Cassella’s Trevi Therapeutics stock options?

The 215,000 Trevi Therapeutics stock options granted to James V. Cassella vest in equal monthly installments. Vesting runs through February 19, 2030, and is conditioned on his continued service with the issuer, meaning he must remain with the company for the options to keep vesting.

What role does James V. Cassella hold at Trevi Therapeutics (TRVI) in this Form 4 filing?

In this Form 4 filing, James V. Cassella is identified as Trevi Therapeutics’ Chief Development Officer. The reported transaction reflects a stock option grant tied to his executive role, with the options held directly in his name under standard service-based vesting conditions through February 19, 2030.

Was the Trevi Therapeutics insider transaction a stock purchase or a compensatory award?

The transaction was a compensatory stock option award, not an open-market stock purchase. The Form 4 classifies it under code A, described as a grant, award, or other acquisition, with an exercise price of $0.0000 per share and service-based vesting over several years.

How many Trevi Therapeutics stock options does James V. Cassella hold after this grant?

After this grant, James V. Cassella holds stock options for 215,000 shares of Trevi Therapeutics common stock. The filing indicates this total as his direct holdings following the transaction, all subject to monthly vesting through February 19, 2030, based on continued service.